Publications and project deliverables
![](https://covirna.eu/wp-content/uploads/2023/03/2.png)
Publications
In the context of the COVIRNA project, consortium members developed the following publications:
- FIMICS: A panel of long noncoding RNAs for cardiovascular conditions (Pub.: 19 Jan 2023)
- Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality (Pub.: 21 Nov 2022)
- (Epi)transcriptomics in cardiovascular and neurological complications of COVID-19 (Pub.: 28 July 2022)
- Evidence for biological age acceleration and telomere shortening in COVID-19 survivors (Pub.: 7 June 2021)
- Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129 (Pub.: 11 Apr 2021)
- Lack of evidence of angiotensin-converting enzyme 2 expression and replicative infection by SARS-CoV-2 in human endothelial cells (Pub.: 6 Jan 2021)
- Joining European scientific forces to face pandemics (Pub.: 4 Dec 2020)
- Call to action for the cardiovascular side of COVID-19 (Pub.: 13 Apr 2020)
![](https://covirna.eu/wp-content/uploads/2023/03/3-1.png)
Deliverables
In its 30 months of activity the COVIRNA project produced a number of deliverables. Below you can find a selection of public deliverables:
- Mediation analysis for understanding direct and mediated effects of lncRNA (D3.2)
- Prediction of MACE (Major Adverse Cardiovascular Events) (D3.3)
- Disease mortality classification (D3.4)
- Design and synthesis of GapmeRs or siRNAs and of expression vectors for target lncRNAs (D4.1)
- Transcriptomic alterations in SARS-COV-2 infected cardiovascular cells (D4.2)
- Functional analysis of inflammatory and vascular cell types (D4.3)
- Project logo, flyer and website (D6.1)
- Communication, dissemination and exploitation plan (D6.2)
- Project video (D6.3)
- Final dissemination event (D6.4)
![](https://covirna.eu/wp-content/uploads/2023/03/1.png)
Communication and dissemination
We committed to connect with all stakeholders, from scientists, clinicians and health managers to patient organisations and the general public. We developed a number of dissemination materials to explain the COVIRNA project, its objectives, methodology, progress and results.
- The project video presents COVIRNA in a simple but compelling language.
- The flyer is a visual two-pager to introduce COVIRNA to the general public.
Our newsletters provided news and updates on the project.
- Newsletter – Issue n. 1 (June 2021)
- Newsletter – Issue n. 2 (Dec 2021)
- Newsletter – Issue n. 3 (June 2022)
- Newsletter – Issue n. 4 (Feb 2023)
- Newsletter – Issue n. 5 (Apr 2023)
We organised events and webinars to present our project to different audiences.
- The key learnings from the session ‘Towards personalised medicine – an innovative diagnostic tool to identify cardiovascular complications in COVID-19 patients‘ during the EHMA 2021 Annual Conference (Sept 2021).
- The report of the session ‘The potential of innovative diagnostic tools: personalised disease management for improved health outcomes in COVID-19 patients’ during the EHMA 2022 Annual Conference (June 2022)
- The report and video recording of the webinar ‘Addressing unmet clinical needs, practices and patient outcomes: the impact of EU-funded projects‘ (Jan 2023)
- The report and video recording of the webinar ‘Patient-centred approaches to Long COVID‘ (Mar 2023)
- The report of the final conference ‘Improving personalised care and patient outcomes through molecular diagnostics and therapy‘ (Apr 2023)
![](https://covirna.eu/wp-content/uploads/2023/03/4-1.png)
Project management
In line with the requirements of the granting authority, we produced technical reports that detail the work conducted during the specific reporting periods.
- Publishable summary – Reporting Period 1 (November 2020 – October 2021)
The report provides an overview of the work carried out in the first year of the project, including achievements, expected results and potential impact. - Publishable summary – Reporting Period 2 (November 2021 – April 2023)
The report provides an overview of the work carried out, including results and impact achieved.